Ocean Biomedical Past Earnings Performance
Past criteria checks 0/6
Ocean Biomedical's earnings have been declining at an average annual rate of -43.5%, while the Biotechs industry saw earnings growing at 16.4% annually.
Key information
-43.5%
Earnings growth rate
-42.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Ocean Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -85 | 10 | 2 |
| 31 Mar 23 | 0 | -79 | 11 | 6 |
| 31 Dec 22 | 0 | -17 | 8 | 8 |
| 30 Sep 22 | 0 | -25 | 12 | 11 |
| 31 Mar 22 | 0 | -24 | 12 | 12 |
| 31 Dec 21 | 0 | -62 | 28 | 34 |
| 30 Sep 21 | 0 | -55 | 24 | 31 |
| 31 Mar 21 | 0 | -46 | 20 | 25 |
| 31 Dec 20 | 0 | -2 | 2 | 0 |
Quality Earnings: OCEA is currently unprofitable.
Growing Profit Margin: OCEA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCEA is unprofitable, and losses have increased over the past 5 years at a rate of 43.5% per year.
Accelerating Growth: Unable to compare OCEA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCEA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.1%).
Return on Equity
High ROE: OCEA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.